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REPORT  FROM  THE  COMMISSION  TO  THE  COUNCIL 
ON  THE  ACTIVITIES 
OF  THE  CO~lf.liTTEE  FOR  PROPRIETARY  1·1EDICINAL  PRODUCTS 
I.  INTRODUCTION 
1.  Subject  of  the  report 
The  present  report  of  the  Commission  to  the  Council  covers  the 
operation  of  the  various  procedures  within  the  framework  of  the 
Committee  for  Proprietary Medicinal  Products  (CPMP),  of  coordination 
of  national  authorizations  to  place  medicines  for  human  use  on  the 
market,  established  by  Community  law1• 
The  Commission  shall,  in  accordance  ~lith  the  first  paragraph  of 
Article  15  of  Council  Directive  75/319/EEC,  as  amended  by  Directive 
83/570/EEC,  "report  to the  Council  every  two  years  on  the  operation of 
the  procedure  laid  down  in  this  chapter  and  its  effects  on  the 
development  of  intra-Community  trade".  As  the  first  applications  made 
in  accordance  with  this  procedure,  called  "multi-State",  were  only 
presented  in  1986,  it  seemed  reasonable  to  allow  sufficient  time  to 
elapse  so  as  to  fully  describe  the operation of  the  ne~1  procedure. 
1In  order  to facilitate the  reading  of  this  report,  texts  of  the  Community 
pharmaceutical  legislation cited  are  summarized  in  chronological  order  in 
annex  I, with  their  publication  references. - 4  -
2.  Content  of  the  report 
It  1s  important  to  consider  this  "multi-State"  procedure  in  relation 
to both,  the  preceding  procedure  which  was  completed  in 1986  and  the 
most  recent  procedure  specifically  designed  for  high  technology 
medicines. 
Indeed,  in  conformity  with  the  time-periods  set  out  in  the  Community 
Directives,  the  Last  applications  made  in  accordance  with  the  old 
procedure  established  by  Directive  75/319/EEC,  were  examined  at  the 
start  of  1986.  It  is  useful  therefore  to  prepare  a  comprehensive 
review  of  the  41  applications  examined  under  that  procedure  between 
1978  and  1986.  This  previous  procedure  has  been  the  subject  of  4 
2  3  successive  reports  and  of  a  more  general  report  which  accompanied 
the  5  proposals  from  the  Commission  to  the  Council  regarding  high 
technology  medicines,  particularly those  produced  by  biotechnology. 
Amongst  these  proposals  adopted  in  the  interim  by  the  Council, 
Directive  87/22/EEC  introduced  in  July  1987,  a  new  Community 
concertation  procedure  applicable  prior  to  all  national  decisions 
concerning  high  technology  medicines,  especially  those  produced  by 
biotechnology,  which  will  be  briefly mentioned  here,  taking  account  of 
its very  recent  introduction. 
With  the  passing  of  the  years,  the  general  role  of  coordination of  the 
Committee  for  Proprietary  Medicinal  Products,  beyond  the  specific 
procedures  mentioned  above,  has  progressively  expanded.  These  other 
activities  of  the  Committee  should  also  be  considered,  especially 
pharmacovigilance  and  the  continuous  updating  of  requirements  and 
practices  in  the  grant  of  marketing  authorizations  in  the  Member 
States of  the  Community. 
------------------------
2Reports  from  the  Commission  to  the  Council  on  the  operation of  the  Committee 
for  Proprietary  Medicinal  Products: 
- COMC79)59  of  22.2.1979; 
- COM(80)149  of  31.3.1980; 
- COM(81)363  of  13.7.1981; 
- COM(82)787  of  3.12.1982. 
3cOM(84)437  of  3.12.1984 - 5  -
3.  Intra  and  extra  Community  trade 
The  number  of  applications  discussed  by  the  Committee  for  Proprietary 
Medicinal  Products  arc still very  few  in  comparison  to  the  hundreds  of 
national  applications  made  separately  each  year  in  each  Member  State. 
Therefore,  there  is  no  scope  for  assessing  the  effect  of  the  various 
Community  procedures  on  the  development  of  intra-Community  trade. 
Nonetheless,  some  key  statistical  information  relating  to  the 
pharmaceutical  industry  in  the  European  Community  has  been  presented 
in  Annex  II  of  this  report.  The  European  pharmaceutical  industry still 
seems  successful.  It  represents  one  quarter  of  the  World  market 
(approximately  25  billions  ECU),  and  more  than  half  of  World 
pharmaceutical  exports,  thus  yieldung  a  positive  trade  balance  for  the 
Community  of  approximately  3.5 billions  ECU.  It  employs  around  40,000 
people  in  the  Community,  of  which  the  level  of  qualification  is 
generally  high.  Unfortunately,  in the  last  twelve  years,  one  can  see  a 
slow  de~line  in  our  market  share  compared  with  the  United  States  and 
Japan,  as  well  as  a  reduction  in  the  number  of  European  new  chemical 
entities at  the  research  and  development  stage  (40~ versus  65r.  for  the 
last  10  years).  One  of  the  reasons  for  this  could  be  the  relatively 
small  size,  with  some  notable  exceptions,  of  European  companies 
compared  to  large  international  firms.  The  size  and  scope  of  a  single 
large  market  will  probably  encourage  the  optimization of  research  and 
production  activities  of  European  firms,  in  order  to  maintain  their 
competitiveness. - 6  -
II.  THE  COMMUNITY  REGULATIONS  AND  RECENT  DEVELOPMENTS  IN  THE  PHARMACEUTICAL 
SECTOR 
1.  Community  pharmaceutical  legislation 
For  more  than  20  years,  the  European  Community  has  contributed  to  the 
improvement  of  the  protection  of  public  health  by  extending  to  all 
Member  States,  old  and  new,  regulations  for  the  placing  on  the  market 
of  medicines  for  human  and  veterinary  use,  guaranteeing  quality, 
safety  and  efficacy  to  the  highest  international  Level  (Annex  I). 
Regarding  access  to  and  maintenance  on  the  market  of  medicines,  the 
Community  experience  is  considerable  and  prevents  now  the  repetition 
of  long  and  expensive tests and  trials in  Europe. 
Five  important  consequences  have  resulted  for  the  circulation  of 
medicines  within  the  Community: 
a)  The  criteria  for  quality,  safety  and  efficacy  of  medicines  have 
been  progressively  harmonized,  as  well  as  certain aspects  of  the 
procedures  for  marketing  authorization  (time-periods,  motivation, 
publication)  or  for  manufacturing  (quality  control,  inspections). 
b)  Analytical,  pharmaco-toxicological  and  clinical  testing  of 
medicines  performed  in  conformity  with  Community  rules  need  not  be 
repeated  within  the  Community. 
c)  Batch  controls,  carried  out  in  the  country  of  origin,  are 
recognized  in  the other  Member  States. 
d)  The  general  requirements  for  Labelling  or  for  the  package  insert 
have  been  harmonized. 
e)  A list  of  colouring  matters  permitted  for  use  in  medicines  has 
been  adopted. - 7  -
For  the  future,  the  up-dating  of  the  technical  requirements  for 
the  testing  of  medicines  has  been  delegated  by  the  Council  to  the 
Commission,  in  accordance  with  the  so-called  Regulatory  Committee 
Procedure,  which  involves  the  participation of  government  experts. 
This  legislation  allows  the  Community  to  exercise  its 
international  competences  in  the  pharmaceutical  sector.  Thus 
regular  contacts  take  place  with  the  USA,  Japan  and  international 
organizations  such  as  the  Council  of  Europe  and  the  World  Health 
Organization. 
2.  The  national  authorities  and  the  Committee  for  Proprietary  Nedicinal 
Products 
Within  the  current  framework  of  Community  regulations,  the  12  Member 
States  remain  fully  responsible  for  deciding  whether  to  grant  or 
refuse  a  marketing  authorization,  in  conformity  with  Community  law.  In 




the  agreed  harmonization  of 
have  been  found  in  the 
regulations,  divergences  of 
decisions  taken  by  national 
authorities  regarding  marketing  authorizations  for 
To  reduce  these  divergences  a  committee  consisting  of 
representatives  of  nember  States  and  the  Commission  was  formed  in 
1977:  the  Committee  for  Proprietary Medicinal  Products  (CPMP). 
This  committee  may  be  invited  by  the  Member  States  or  the  Commission 
to  give  an  opinion,  of  an  advisory  nature,  on  particular  medicines, 
especially  for  monitoring  side-effects  of  medicines  (phnrmaco-
vigi lance).  The  Committee  can  also  be  called  upon  by  pharmaceutical 
firms  in  accordance  \Jith  the  various  Community  procedures,  designed  to 
facilitate  the  adoption  of  a  common  position  among  Member  States 
regarding  marketing  authorizations,  and  their  operation  will  be 
described  later. 
The  t,1cmbers  of  the  Committee  are  expressly  charged  in  the  Member 
States  and  the  services  of  the  Commission  with  matters  relating to  the 
authorization of  medicines;  they  elect  amongst  themselves  a  president 
and  a  vice-president  for  a  3  year  term,  renewable  once;  the  Commission 
nominates  the  other  vice-president  and  acts  as  secretariat  to  the 
Committee.  The  presidency  of  the  Committee  has  moved  successively  from 
Mr  L.  Robert  (Luxembourg)  to  Dr  C.A.  Teijgelcr  (Netherlands). - 8  -
Following  election,  the  vice-presidents  have  been  Pr  D.  Poggiol ini 
<Italy),  Pr  B.  Schnieders  (Germany),  then  Dr  G.  Jones  (UK).  The  list 
of  members  of  the  Committee  is given  in  Annex  III. 
3.  The  pharmaceutical  proposals  of  the  White  Paper 
The  role  of  the  Community  is  to  ensure  a  favourable  regulatory 
environment  for  this  industry  which  is already  over-regulated,  whilst 
also supporting  the protection of public  health  and  its improvement  by 
increased development  of  pharmaceutical  research  in  Europe. 
This  has  led  the  Commission  to  propose  13  specific  initiatives  in  the 
pharmaceutical  sector,  in  its  White  Paper  on  the  completion  of  an 
internal  market. 
Six  measures  are already  adopted  and  in force: 
4  directives  of  December  1986  in  favour  of  high  tech/biotech 
medicines; 
- a  new  recommendation  of  February  1987  on  the  testing of  drugs; 
- a  communication  of  December  1986  from  the  Commission  on  the 
compatibility  with  Article  30  of  the  EEC  Treaty  of  price  control 
measures. - 9  -
Three  initiatives  have  been  submitted  to  the  Council  at  the  beginning 
and  end  of  1987: 
- a  proposal  for  a  directive  on  to  the  transparency  of  national 
measures  relating  to  the  control  of  prices of  medicinal  products  for 
human  use  and  their  inclusion  \~ithin  the  scope  of  the  national 
health  insurance  systems4; 
- a  proposal  regarding  the  adhesion  of  the  European  Community  to  the 
Convention  on  the  elaboration  of  an  European  Pharmacopoeia  and  a 
report  on  the  implementation of  the  mandate  for  negotiation  given  by 
Council  on  26  May  19875; 
- 4  proposals  to  extend  the  Directives  to  cover  medicines  not  already 
included6. 
Four  further  initiatives are  the  subject  of  preparatory  ~ork and  ~Jill 
be  sub~itted to  Council  in  due  course: 
- amendment  of  the  Directives  relating to veterinary  medicines, 
- selection  of  a  definitive  system  for  free  circulation  (mutual 
recognition  or  a  single  authorization,  applicable  throughout  the 
Community), 
-harmonization of  the  conditions of  delivery  of  medicinal  products  to 
patients  (over-the-counter  and  prescription  medicaments), 
improvement  of  the  information  for  doctors  and  patients  ~ith  a  vie~ 
to  more  rational  use  of  medicines. 
4~~~~~~~;~~-~;-~;~~~~~~~6 and  OJ  C 17  of  23.1.1987 
5sEC(86)2010  of  15.12.1986 and  SEC<87)2001  of  21.12.1987 
6cOM(87)697  of  4.1.1988,  OJ  C 36  of  8.2.1988 - 10  -
III.  REVIEW  OF  THE  FORMER  PROCEDURE  OF  DIRECTIVE  75/319/EEC  (1978-86) 
1.  The  former  procedure 
It  is  useful  to  recall  that  the  procedure  established  by  Articles  9  to 
11  of  Directive  75/319/EEC  allowed  a  company  to  request  a  marketing 
authorization  in  five  or  more  Member  States,  after  having  obtained  a 
first  authorization  in  accordance  with  Community  Directives.  During 
the  time-period  of  120  days  for  the  examination  of  the  application, 
the  f·1ember  States  concerned  could  raise  reasoned  objections,  giving 
rise  to  an  opinion  of  the  CPMP,  which  had  to  be  given  within  60  days 
and  follm·Jed  within  30  days  by  a  statement  from  the  ~1ember  States 
concerned  on  their position. 
2.  The  operation of  the  former  procedure 
This  procedure  was  hardly  used  by  the  pharmaceutical  industry,  which 
led  the  Commission  to  propose  substantial  improvements  resulting  in 
the  multi-State  procedure.  The  essential  details  of  the  41 
applications  made  between  1978  and  1985  are  given  in  Annex  IV  of  this 
report.  This  sample  is  too  small  to  allow  a  satisfactory  statistical 
extrapolation.  These  41  dossiers  covered  a  total of  253  (individual) 
marketing  applications  made  to  5  Member  States  or  more.  After  a  slow 
start,  the  number  of  applications  increased  from  1980  to  1983,  and 
declined  thereafter.  Amongst  those  countries  which  had  given  the 
initial  authorization,  the  UK  is  most  evident  with  16  of  the  41 
dossiers,  followed  by  France  (7)  and  Denmark  (7),  Germany  (5),  Belgium 
(5)  and  lastly  Ireland  (1).  Of  those  countries  receiving  applications, 
the  Benelux  is  the  most  frequent  recipient:  Luxembourg  (37), 
Netherlands  (35)  and  Belgium  (33),  then  Italy  (28),  Denmark  (28), 
Germany  (25),  Ireland  (24),  UK  (18),  France  <15),  and  Greece  <12).  Due 
to  the  date  of  their  accession  to  the  Community,  Spain  and  Portugal 
were  not  concerned  by  this  procedure  and  Greece  was  involved  only 
since  1981. - 11  -
3.  The  companies  concerned 
This  procedure  therefore  has  involved  the  competent  authorities  of  all 
Member  States.  It  is  interesting  to  note  for  these  41  dossiers  the 
country  of  origin  of  the  firms  concerned,  on  the  basis  of  available 
information: 
9  companies  from  USA  <11  dossiers),  7  French  <7  dossiers),  4  Danish 
(11  dossiers),  3  German  (3  dossiers),  3  S~wdish  (3  dossiers),  1 
Belgian  (3  dossiers),  1  UK  (1  dossier),  1  Dutch  <1  dossier)  and 
1  Swiss  (1  dossier). 
Furthermore,  a  majority  of  applications  came  from  medium-sized 
pharmaceutical  entreprises,  as  against  only  9  applications  from 
multinationals  which  are  normally  Listed  in  the  top  35  pharmaceutical 
companies  in  the  World.  Only  a  small  number  of  applications  concerned 
new  chemical  entities. 
4.  The  outcome  from  the  former  procedure 
So  as  to  facilitate  analysis  of  the  position,  o  ~10rking  group  has 
graded  the  41  opinions  given  by  the  CPMP  according  to  a  scale 
consisting  of  7  levels,  going  from  an  unanimously  favourable  opinion 
(grade  1)  to  an  unanimously  unfavourable  opinion  (grade  7).  It  emerges 
from  this  that  28  opinions  uere  favourable  of  which  20  were  unanimous, 
whilst  13  were  unfavourable  of  which  5  were  unanimous.  In  other  words, 
only  one  half  of  the  initial  authorizations  given  by  one  Member  State 
were  in  principle acceptable  to all other  Member  States,  on  the  basis 
of  the  same  harmonized  legislation.  The  253  applications  coming  from 
these  41  dossiers  resulted  in  175  marketing  authorizations  and  63 
definite  refusals.  15  cases  remain  suspended  generally  because  the 
company  has  not  supplied  the  Member  State  with  the  additional 
information  requested,  following  the  opinion  of  the  Committee.  Half  of 
the  definitive  decisions  have  been  taken  in  the  year  following  the 
opinion  of  the  Committee,  ~lith  the  exception  of  Italy  where  there 
exists  an  administrative  practice  which  ties  the  marketing 
authorization  to  the  fixing  of  price  and  is  the  subject  of  an 
infraction  procedure  under  Article  169  of  the  EEC  Treaty.  It  is, 
however,  worrying  to  note  that  the  other  half  of  definitive decisions 
have  taken  more  than  1  year  and  as  much  as  4  years  in  extreme  cases, 
after  the  opinion  of  the  Committee. - 12  -
IV.  THE  "MULTI-STATE''PROCEDURE,  INTRODUCED  IN  1986  BY  DIRECTIVE  83/570/EEC 
1.  The  new  rules  of  the  "multi-State"  procedure 
In  adopting,  on  the  proposal  from  the  Commission,  Directive 
83/570/EEC,  the  Council  reformed  many  important  aspects  of  the 
previous  procedure  which  had  been  established  by  Directive  75/319/EEC. 
In  the  first  place,  ~1ember  States  must  1n  future  take  into  due 
consideration  the  initial  authorization,  save  in  exceptional  cases 
when  they  refer  reasoned  objections  to  the  opinion  of  the  Committee. 
Secondly,  to  make  the  procedure  more  attractive,  the  minimum  threshold 
of  Member  States  concerned  has  been  reduced  from  5  to  2,  and  firms 
have  at  their disposal  direct  access  to  the  Committee  by  virtue of  the 
introduction  of  the  right  to  a  hearing  - which  does  not  exist  in  many 
national  procedures.  Thirdly,  in order  to  be  in  a  position to  reach  a 
decision  ~ith full  knowledge  of  the  facts,  the  Member  States  concerned 
have  at  their  disposal  a  detailed  description  of  the  content  of  the 
initial  authorization  in  the  form  of  a  "summary  of  product 
characteristics"  as  well  as  a  critical  evaluation  report  prepared  by 
the  original  country,  at  least  in  the  case  of  new  medicines.  It  is 
important  however  to point  out  that  the  procedure  remains  optional  for 
the  companies  and  that  the  opinions  of  the  Committee  are  not  legally 
binding  on  the  Member  States. 
2.  The  operation  of  the  multi-State  procedure 
Resulting  from  these  improvements,  the  multi-State 
proven  more  attractive  to  pharmaceutical  firms  as, 
dossiers  have  been  submitted  until  February  1988. 
procedure 
since  1986, 
has 
36 
From  the  point  of  view  of  countries  concerned,  the  tendencies  of  the 
previous  procedure  linger  in  the  multi-State  procedure.  Spain  just 
joined  the  procedure  in  1986,  while  Portugal  has,  by  virtue  of  the 
Treaty  of  Accession,  a  transitional  period of  5  years  to  implement  the 
pharmaceutical  Directives.  The  List  of  countries  considered  most 
reliable  by  the  companies  as  the  starting  point  for  the  procedure 
confirms  the  previous  experience.  The  UK  still  leads  the  countries  who 
have  granted  the  initial  authorization,  with  14  dossiers  out  of  36, 
followed  by  France  (9),  Germany  (5),  Ireland  <3>,  Belgium  (2)  and 
Denmark  (2),  Italy  (1). - 13  -
Regarding  countries  receiving  applications,  the  order  is  as  follo~s: 
Belgium  (23),  Luxembourg  (22),  Greece  (21),  Italy  (21)  and  Germany 
(21),  Netherlands  (19>,  Spain  (18),  Denmark  (16),  UK  (13),  Ireland 
<12)  and  France  <12).  These  36  multi-State  dossiers  cover  198 
individual  national  applications,  ~lith  an  average  of  a  Little  more 
than  5  States  per  application,  and  this  is despite  the  lowering  of  the 
obligatory  threshold  to  at  Least  2  Member  States  as  indicated  above. 
Taking  account  of  the  usual  time-periods  of  the  procedure  and  the 
additional  time  requested  by  the  companies  in order  to better  prepare 
their.  responses  or  hearings,  the  Committee  has  rendered  20  opinions  to 
date,  of  which  17  were  favourable.  Companies  have,  in  7  cases,  had 
recourse,  at  their  request,  to  a  hearing  ~Jith  the  Committee. 
3.  Preliminary  analysis  of  results 
It  is unfortunate that,  to date,  every  dossier  has  systematically  been 
the  subject  of  reasoned  objections,  in  spite  of  the  obligation  on 
Member  States  to  take  due  consideration  of  the  initial authorization, 
save  in  exceptional  cases.  In  this  system,  similar  legally  to  the 
model  for  mutual  recognition  of  marketing  authorizations,  the 
safeguard  clause,  in  this  case  the  opinion  of  the  Committee,  is  in 
fact  systematically  used  by  Member  States;  and  this despite  the  fact 
that  the  initial  nuthorizations  were  given  by  a  Limited  number  of 
national  authorities  whose  scientific  competence  is  internationally 
renowned.  The  political  willingness,  declared  by  certain  Member 
States,  to  adopt  the  principle  of  mutual  recognition,  has  not  yet 
translated  itself  into  the  actual  administrative  practice  of  the 
competent  authorities  in  granting authorizations  in  these  same  Member 
States.  If  the  multi-State  procedure  is  to  serve  as  a  testing  ground 
leading  to  a  system  of  mutual  recognition  of  authorizations,  the 
expcr·ience  thus  far  is  not  very  convincing.  While  within  the  CPMP,  the 
introduction  of  the  multi-State  procedure  was  accompanied  by  a 
remarkable  development  of  co-operation  between  the  national  delegates 
and  their  experts,  the  national  committees  responsible  for  the 
scientific evaluation of  medicines  have  not  always  given  the  necessary 
priority  to  reinforce  this  European  co-operation  which  they  have 
followed  rather  than  supported. - 14  -
4.  The  crisis of  national  authorization procedures 
Apart  from  a  certain  lack  of  information,  progressively  filled  in  by  a 
multiplicity  of  symposia  on  the  European  procedures,  and  the  natural 
fear  of  these  national  committees  to  see  their  own  influence  diminish, 
the  relative  inertia  of  national  authorities  can  be  attributed  to  the 
serious  crisis  which  they  have  encountered  over  the  last  number  of 
years  in  most  of  the  national  authority  systems.  In  fact,  since  the 
beginning  of  the  80's,  the  number  of  applications  has  more  than 
doubled  in  all  industrialized  countries,  combined  with  increasing 
scientific  complexity  of  the  dossiers,  whilst  the  human  and  material 
resources  have  generally  evolved  more  slowly,  indeed  even  stagnated. 
In  the  area  of  high  technology,  only  some  countries  have  available 
competent  experts,  and  even  these  arc  limited  in  number.  This  results 
in  a  progressive  lengthening  of  the  delays  in  authorization,  to  the 
detriment  especially of  patients  and  European  pharmaceutical  research. 
To  avoid  these  delays  and  the  long  national  waiting  lists,  companies 
have  turned  more  and  more  to  the  multi-State  procedure,  which  risks 
being  overloaded  in  its  turn  as  it is  in  effect  dependant  upon  the 
smooth  operation of  the  national  systems. 
5.  Development  of  the  Committee 
The  CPMP,  ~1hich  has  not  been  equipped  with  its  own  resources,  has 
available  only  a  tiny  secretariat,  provided  by  the  services  of  the 
Commission.  The  principle of  mutual  recognition  wl1ich  under-writes  the 
multi-State  procedure  introduced  by  Directive  83/570/EEC,  should  mean 
that  only  a  limited  number  of  exceptional  cases  \lould  require  an 
opinion  of  the  Committee,  the  Member  States  taking  into  due 
consideration,  in  the  grent  majority  of  cases,  the  initial 
authorization.  The  ability of  the  Committee  to  for~ulate opinions  for 
the  Member  States  and  the  Commission  would  be  totally saturated if the 
number  of  cnses  submitted  were  to  go  beyond  several  dozen  dossiers  per 
year.  The  Committee  is neither  equipped  nor  legally mandated  to  become 
a  systematic  appeal  authority against  national  decisions:  it would  be 
necessary  then  to  radically  change  the  system. 
On  the  initiative  of  the  president  and  vice-presidents  of  the 
Committee  and  its secratariat,  initial considerations  are  in  hand  to 
improve  the  practical  operation  of  the  Committee,  and  to  suggest 7 
- 15  -
ultimately alternative operational  rules.  Thus,  the  various  steps  of 
the  multi-State  procedure  have  been  clarified and  the  Member  State of 
origin  is usually  designated  as  rapporteur,  particularly to facilitate 
the  liaison  with  the  company,  the  other  concerned  countries  and  the 
secretariat  (sec  Annex  V). 
6.  A standard  format  for  marketing  authorization  applications  in  Europe 
Immediately  after the  adoption  of  Directive  83/570/EEC,  the  Commission 
began  examining,  with  the  help  of  an  ad  hoc  group  of  the  CPMP  led  by 
Prof.  Poggiolini  <Italy),  the  possibility  of  preparing  a  common 
standard  format,  acceptable  to  all  the  Member  States,  for  the 
presentation  of  applications  and  a  simplification  of  language 
requirements.  The  result  was  a  guide  entitled  "Notice  to  applicants 
for  marketing  authorization for  proprietary  medicinal  products  in  the 
Member  States  of  the  European  Community  on  the  use  of  the  new 
multi-State  procedure  created  by  Council  Directive  83/570/EEC", 
published  for  the first  time  in  1986  (see  Annex  I, N.B.). 
The  competent  authorities  have  since  then  accepted  the  extension  of 
the  use  of  this  single  format  to  all  national  and  Community 
applications,  on  the  basis  of  a  draft  revised  notice,  lengthily 
discussed  with  the  representative  authority  of  the  European 
pharmaceutical  industr/  and  distributed  by  them  under  the  title  of 
"Notice  to  applicants  for  marketing  authorizations  for  proprietary 
medicinal  products  in  the  Member  States  of  the  European  Community", 
which  will  be  published  in  due  course.  This  standardization,hailed as 
major  progress  by  the  pharmaceutical  industry,  reduces  considerably 
the  administrative  burden  of  companies  and  assigns  major  importance  to 
the  summary  of  the  dossier;  this  avoids  particularly  the  systematic 
manipulation  of  a  full  dossier,  the  volume  of  which  can  sometimes  be 
several  cubic  metres.  The  standard  EEC  format  has  been  largely 
accepted  by  the  other  countries  of  Hestern  Europe  and  could  in  the 
future  serve  as  the  basis  for  international  harmonization  (see 
Annex  VI>. 
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V.  THE  PROCEDURE  RESERVED  FOR  r-1EDICINES  OF  HIGH  TECHNOLOGY  ACCORDING  TO 
DIRECTIVE  87/22/EEC,  IN  OPERATION  SINCE  JULY  1987 
1.  The  new  procedure of  Directive  87/22/EEC 
For  high  technology/biotechnology  medicines,  Directive  87/22/EEC 
obliges  the  competent  authorities  to  consult  each  other  within  the 
Committee  for  Proprietary  Medicinal  Products  before  deciding  to 
authorize,  refuse  or  withdraw  a  high  technology  medicinal  product. 
With  effect  from  1  July  1987,  this  consultation procedure  will  apply 
systematically  for  biotechnology,  which  is  considered  to  be  a  priority 
by  the  Community  and  in  the  case  of  other  high  technology  medicinal 
products,  at  the  request  of  the  firm  concerned.  In  the  annex  to  the 
Directive,  these  medicinal  products  are  defined  by  two  lists.  List  A 
comprises  medicinal  products  derived  from  new  biotechnological 
processes  (recombinant  DNA,  hybridomes/monoclonal  antibodies  and  cell 
cultures).  List  B  comprises  several  other  categories  of  high 
technology  medicinal  products  which,  in  the  opinion of  the  competent 
authorities,  must  constitute a  significant  innovation.  The  principal 
steps  of  this  procedure  are  illustrated in  Annex  VII. 
2.  The  protection of  innovation 
High  technology  medicinal  products  which  have  followed  the  new 
procedure  will  benefit  from  a  certain  form  of  market  exclusivity  for  a 
period  of  ten  years  running  from  the  date  of  the  first  authorization 
to  market  the  product  within  the  Community.  This  ten  year  period  may 
in  certain  cases  extend  the  protection  offered  by  patent.  The 
protection  conferred  by  patent  law,  and  in  particular  the  Munich 
Convention  on  the  European  Patent,  is  often  insufficient  because  the 
maximum  period  of  20  years  protection  is  frequently  reduced  by  the 
time  taken  to  complete  testing and  obtain authorization.  In  addition, 
the  current  protection  offered  by  patent  law  for  biotechnology 
inventions  is generally not  considered to be  completely  satisfactory. - 17  -
The  solution  ndopted  by  the  Community  in  Directive  87/21/EEC  mainly 
requires  the  copier: 
- either  to  obtain  the  consent  of  the  innovatory  firm  to  refer  to  the 
originnl  tests, 
- or  to  ~.Jait  ten  years  fror:1  the  dnte  of  the  first  nuthorizntion  to 
market  the  "high  technology  medicinnl  product"  ~lithin  the  Community 
before  being  nblc  to  present  nn  npplicntion  in  simplified  form 
covering  primarily  the  quolity  of  the  product  nnd,  if necessnry,  its 
bio<~vnilnbility.  This  mechanism  of  protection  is  elnborated  in 
detail  in  Annex  VIII. 
3.  Operntion  of  the  procedure  of  Directive  87/22/EEC 
Anticipating  the  ndoption  of  Directive  87/22/EEC,  nnd  thnnks  to  the 
good  co-operntion on  the  pnrt  of  competent  nuthorities,  the  Committee 
has  hnd  experience  of  nn  applicntion  introduced  by  France  regnrding  n 
monoclonnl  antibody  designed  to  prevent  the  rejection  of  rennl  grnfts 
nnd  hnd  given  n  fnvournble  opinion  in  June  1986  on  the  mntter. 
Since  the  entry  into  force  of  Directive  87/22/EEC,  in  July  1987,  the 
Committee  hns  so  for  only  received  3  new  opplicntions  for  \lhich  its 
referrnl  was  obligatory  <List  A),  with  Denmark  and  France  as 
rapporteur  countries;  the  consideration  of  these  npplications  is 
currently  under  \.Jny. 
It  would  be  premnture  nt  this  point  to  drnw  conclusions  from  this  new 
procedure  which,  while  fundnmentally  national,  nontheless  represents  a 
signifi cnnt 
npplicable 
step  in  the  direction  of  a 
throughout  the  Community. 
single  evnluation 
The  crisis  of 
which  is 
nntional 
nuthorization  systems,  mentioned  above,  is  nlso  likely  to  affect 
countries  acting  as  rapporteur  in  conformity  with  Directive  87/22/EEC. 
But  this  co-ordinated  procedure  presents  for  the  Member  States  a  first 
interesting  opportunity  to  pool  the  expertises  availnble  and  to 
attempt  to  compens<1te  for  the  deficiencies  of  individual  authorities 
working  in  isol~tion. - 18  -
VI.  OTHER  ACTIVITIES  OF  THE  COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
1.  Emergency  measures  and  pharmacovigilance 
In  accordance  with  the  Directives,  the  competent  authorities  of  the 
Member  States  are  obliged  to  exchange  all  appropriate  information  in 
order  to  guarantee  the  quality,  safety  and  efficacy  of  medicinal 
products.  In  addition  they  must  immediately  inform  the  Committee  for 
Proprietary  Medicinal  Products  of  any  refusal  or  withdrawal  of  a 
marketing  authorization  and  of  any  prohibition  on  supply.  In 
association  with  the  Member  States,  the  Commission  has  instituted  a 
system  of  exchange  of  information  about  the  dangers  resulting  from  the 
use  of  medicinal  products.  A  constantly  updated  list  of  contact 
persons  makes  possible  the  rapid  exchange  of  urgent  information  by 
telex  or  telefax. 
Every  two  months,  if  necessary  every  month,  the  Committee  for 
Proprietary  Medicinal  Products  considers  questions  linked  to  the 
adverse  effects  of  medicines.  The  Committee  also  takes  into  account 
questions  raised  in  the  European  Parliament  and  contributions  coming 
from  the  European  consumer  organizations.  This  pharmacovigilance  work 
has  considerably  intensified  over  the  past  few  years,  and  currently 
covers  some  ten  to fifteen  products  at  each  meeting. 
~ledicines  thus  examined  become  the  subject  of  an  information  sheet, 
which  indicates  their status  in  the  12  Member  States.  These  sheets  are 
updated  and  collated  in  a  confidential file sent  every  2  months  to  the 
competent  authorities.  The  exchange  of  this  information  could  be 
facilitated  by  the  installation,  during  the  next  2  years,  of  a 
computerized  system. 
At  the  request  of  a  Member  State,  the  Committee  can  prepare  an  opinion 
on  unwanted  side-effects.  In  this  context,  and  as  an  example,  an 
important  opinion  was  given  in  July  1986  on  the  use  of  aspirin  in 
children  and  the  so-called  Reye's  Syndrome;  in  May  1987,  after  a 
hearing  with  the  company,  an  unfavourable  opinion  regarding  the 
continued  marketing  of  Suprofen,  an  analgesic,  was  given. - 1':1  -
The  president  of  the  Committee  and  the  representative  of  the 
Commission  have  requested  a  modification  of  the  internal  rules  of  the 
Committee,  in  order  to  allow  greater  public  dissemination  of  the 
conclusions  of  the  Committee  when  a  medicine  is  in question. 
2.  Working  Parties established  by  the  Committee 
In  association  with  the  Committee  for  Proprietary  Medicinal  Products, 
preparatory  work  is  undertaken  in  order  to  codify  and  harmonize  the 
detailed  national  practices  in  the  implementation  of  the  existing 
Community  Directives  and  to  prepare  the  technical  updating  of  the 
Directives.  The  Pharmaceutical  Committee,  which  consists  of  the 
Directors-General  for  pharmacy  in  the  national  ministries  of  health, 
and  which  meets  about  twice  a  year,  is  also  consulted  on  these 
measures.  This  work  has  already  been  conveyed  by  two  Recommendations 
on  the  testing  of  medicines  (83/571/EEC  and  87/176/EEC)  and  by  the 
publication of  the  notice  to  applicants  mentioned  above.  The  work  is 
continuing,  with  the  participation  of  about  one  hundred  government 
experts  and  in  close  consultation  with  the  European  pharmaceutical 
industry,  in  the  following  working  parties: 
a)  The  Quality of  rledicines  Working  Party,  chaired  by  Dr.  Cartwright 
(United  Kingdom),  has  prepared  or  is  considering  guidelines  on 
stability,  chemistry  of  the  active  ingredient,  development 
pharmaceutics  and  process  validation,  analytical  validation  and 
some  improvements  to  the  Directives;  a  sub-group  led  by 
Dr.  Hefendehl  (Germany)  is  involved  with  the  quality  of  herbal 
remedies;  another  sub-group  led  by  Dr.  Kristensen  (Denmark)  is 
involved  with  radiopharmaceuticals. 
b)  The  Biotechnology/Pharmacy  Working  Party,  chaired  by  Dr.  Schild 
<United  Kingdom)  has  prepared  3  guidelines  on  the  quality  of 
medicines  derived  from  recombinant  DNA  technology,  monoclonal 
antibodies  ns  well  as  on  the  safety  testing  of  medicines  from 
biotechnology;  it advises  the  Committee,  in  its consideration of 
these  medicines,  as  well  as  the  Commission,  on  the  extension  of 
the  Directives  for  biotechnology  products,  especially  vaccines. - 20  -
c)  The  Safety  of  nedicines  Working  Party,  chaired  by  Prof.  Bass 
(Germany)  studies  particularly  Local  toxicity  testing  and 
preclinical safety  trials of  medicines  produced  by  biotechnology, 
in  conjunction  with  the  above  group. 
d)  The  Efficacy  of  f.1edicines  Harking  Party,  chaired  by 
Prof.  Alexandre  (France),  has  finalized  the  "general  rules  and 
scientific  principles  for  the  conduct  of  clinical  trials"  which 
were  adopted  by  the  Committee  in  July  1987.  Work  is  in  hand  on 
guidelines  for  clinical  trials  in  the  elderly  and  chiLdren,  on 
anti-depressants,  anti-arrhythmics  and  cardiac  insufficiency;  a 
sub-group  is  looking  at  anti-cancer  medicines,  with  the 
participation  of  E.O.R.T.C.  (European  Organization  for  Research 
and  Treatment  of  Cancer). 
, e)  The  ad  hoc  group  on  the  Evaluation  Report,  chaired  by 
Prof.  Poggiolini,  has  prepared  the  "Notice  to  Applicants"  relating 
to  a  standard  European  format  for  marketing  applications,  in 
conjunction  with  the  chairmen  of  the  other  working  parties; 
Annex  II  of  the  Notice,  which  concerns  expert  reports,  is  in  the 
course  of  revision. 
f)  Lastly  the  activities of  the  drafting  group  for  the preparation of 
an  "EEC  guide  to Good  nanufacturing  Practices  (G.H.P.)",  chaired 
by  Dr.  B.  Hartley  (United  Kingdom),  whilst  not  directly  Linked  to 
the  Committee,  usefully  completes  the  work  of  technical 
harmonization. 
3.  International  spin-off of  the  Committees  activities 
On  the  World  scene,  the  Community  has  shown  its commitment  to  support 
international  co-operation,  in particular to  guarantee  the quality of 
medicines  exported  to  third  countries  and  to  supply  necessary 
ir.formation  to  developing.  This  stance  has  been  defended  at  the  World 
Health  Assembly,  as  well  as  at  the  4th  meeting  of  I.C.D.R.A. 
(Inttrnational  Conference  of  Drug  Regulatory  Agencies)  held  under  the 
aegis  of  the  \-Jorld  Health  Organization,  at  which  the  president, 
vice-presidents  and  several  members  of  the  Committee  actively 
participated. - 21  -
The  Committee  and  the  chairmen  of  the  Working  Parties  equally  provide 
technical  ~upport  to  the  Commission  in  bilateral  discussions.  For 
example,  after  the  success  in  July  1984  of  an  initial technical visit 
to  Tokyo  by  pharmaceutical  experts  of  the  Committee,  a  second  visit  is 
in  preparation  for  1988. 
At  the  European  level,  contacts  were  increased  with  the  Council  of 
Europe,  which  in  the  pharmaceutical  sector  has  many  technical 
activities  complementary  to  those  of  the  Community,  in  the  form  of  the 
Europenn  Pharmacopoeia,  the  Committee  of  experts  on  pharmaceutical 
questions  (Partial  Agreement),  and  the  Committee  of  experts  on  the 
blood  transfusion.  Close  connections  have  also  been  established  with 
the  Nordic  Council  of  Mcdi cine  and  the  system  of  the  Convention  of 
Pharmaceutical  Inspections  (PIC)  related  to  the  European  Free  Trade 
Association. 
4.  Other  activities of  interest  to the  Committee 
The  achievement  of  a  single  market  by  1992  implies  not  only  the  free 
circulation of  medicines,  but  also  a  much  greater  harmonization  of  the 
essential  information  accompanying  these  medicines,  such  as  the  main 
indications  and  their  dosage  regimen,  contra-indications  and 
precautions  for  use.  1\  study  initiated  in  1985  for  the  Committee  by 
Prof.  Poggiolini,  and  which  will  be  completed  in  1988,  shows  that  the 
great  majority  of  preparations  marketed  in  all  the  European  markets 
are  based  on  only  a  few  hundreds  of  common  active  principles.  The 
Committee  could  act  as  the  forum  to  compare  the  summaries  of  product 
characteristics  of  a  limited  number  of  the  medicinal  products, 
appropriately  selected  so  as  to  advise  the  Commission  on  the  best 
means,  in  the  future,  of  reducing  the  obvious  differences  in  the 
information  accompanying  these  hundreds  of  medicines  of  European 
significance. 
In  order  to  improve  information  for  European  patients,  and  in 
compliance  with  the  conclusions  of  the  Council  of  Ministers  of  Health 
of  15  May  1987,  the  Commission  organized,  at  the  end  of  1987,  the 
first  meeting  with  representatives  of  the  European  Consumers 
Organizations  and  the  pharmaceutical  industry,  i.e.  EFPIA  and  AESGP8• 
0-----------------------
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For  many  years,  considerable  attention  has  been  paid  to  rare diseases 
which  do  not  benefit  from  adequate  treatment  because  the  number  of 
affected patients is  low.  The  cost  of  pharmaceutical  research  for  such 
so-called  "orphan"  drugs  is generally dissuasive  on  industry. 
Neither  the  European  Community,  nor  its  ~!ember  States,  currently  have 
any  special  Legislation  for  orphan  drugs,  comparable  to  the  "US  Orphan 
Drug  J\ct"  of  1983.  Ho~1ever,  certain  aspects  of  the  Community 
pharmaceutical  regulations  can  already  favour  the  access  to  the 
European  market  of  orphan  drugs  and  can  assure  them  some  protection. 
An  exemption  is  already  expressly  foreseen  for  orphan  drugs  by  the 
follmring  terms,  from  point  5  of  the  Last  chapter  of  Directive 
75/318/EEC: 
"5.  ~Jhen,  1n  respect  of  particular  therapeutic  indications,  the 
applicant  can  show  that  he  is unable  to  provide  comprehensive  data 
on  therapeutic  efficacy  and  safety  under  normal  conditions of  use, 
because  the  indications  for  ~1hich  the  product  in  question  is 
intended  are  encountered  so  rarely  that  the  applicant  cannot 
reasonably  be  expected  to  provide  comprehensive  evidence," 
In  such  a  case,  the  marketing  authorization  may  be  granted  on 
conditions  such  as  administration  under  medical  supervision,  possibly 
in  a  hospital  and  uith  inform<Jtion  to  the doctor  on  the  incompleteness 
of  the  available data. 
Some  orphon  drugs  could  also  benefit  from  the  advantages  of  the 
procedure,  introduced  by  Directive  87/22/EEC,  which  is especially open 
to  "medicinal  products  containing  a  nell  subst<:mce  or  an  entirely  new 
indication which,  in the  orinion of  the  competent  authority  concerned, 
is  of  significant  therareutic  interest"  as  uell  as  those  "medicinal 
products  administered  by  means  of  new  delivery  systems  which,  in  the 
opinion  of  the  competent  authority  concerned,  constitute a  significant 
innovation
11
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VII.  CONCLUSION 
In  accordance  with  Article  15  of  Directive  75/319/EEC  as  amended,  and  also 
with  the  Legislative  programme  set  out  in  the  White  Paper  on  the  Internal 
Market,  in  the  Light  of  experience,  the  Commission  must,  before 
1  November  1989,  submit  to  the  Council  a  proposal  containing appropriate 
measures  Leading  towards  the  abolition  of  any  remaining  barriers  to  the 
free  movement  of  medicinal  products  within  the  Community.  The  Commission 
hopes  that  the  presentation of  this  report,  which  describes  the  experience 
acquired  within  the  Committee  for  Proprietary  Medicinal  Products  to date, 
will  serve  as  a  basis  for  reflexion  by  the  f1cmber  States  and  interested 
parties  as  to  the  form  which  any  definitive  system  for  the  free  movement 
of  medicinal  products  might  take  (mutual  recognition,  a  centralized 
Community  system  or  an  intermediate  approach). 
The  Commission  therefore  invites  those  concerned  to  submit  comments  on 
this question  and  also their  comments  and  suggestions  on  the  other matters 
described  in  this  report.  Any  contributions  should  be  addressed,  before 
1  September  1988,  to: 
Service  III /B-6 
"Pharmaceuticals,  Veterinary  Medicines" 
Directorate-General  for  Internal  Market  and  Industrial  Affairs 
Commission  of  the  European  Communities 
200,  rue  de  La  Loi 
B-1049  Brussels 
Before  the  end  of  1988,  the  services  of  the  Commission  ui ll  prepare  a 
memorandum  which  will  summarize  the  comments  received  and  set  out 
provisional  conclusions  which  will  serve  as  a  basis  for  consultation 
during  the  elaboration of  detailed  formal  proposals  in  1989. - 24  -
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ANNEX  I 
RULES  GOVERNING  PHARMACEUTICALS  IN  THE  EUROPEAN  COMMUNITY 
- COUNCIL  DIRECTIVE  65/65/EEC  of  26  January  1965  on  the  approximation  of 
provisions  laid  down  by  law,  regulation or administrative action  relating 
to  proprietary  medicinal  products  (O.J.  n°  22  of  9.2.65). 
- COUNCIL  DIRECTIVE  75/318/EEC  of  20  May  1975  on  the  approximation  of  the 
Laws  of  Member  States  relating  to  analytical,  pharmacotoxicological  and 
clinical  standards  and  protocols  in  respect  of  the  testing  of  proprietary 
medicinal  products  (O.J.  n°  L 147  of 9.6.75). 
- COUNCIL  DIRECTIVE  75/319/EEC  of  20  May  1975  on  the  approximation  of 
provisions  laid  do~Jn  by  law,  regulation or  administrative action  relating 
to proprietary  medicinal  products. 
- COUNCIL  DIRECTIVE  78/25/EEC  of  12  December  1977  on  the  approximation  of 
the  laws  of  the  Member  States  relating  to the  colouring matters  which  may 
be  added  to  medicinal  products  (O.J.  n°  L 11  du  14-1.78). 
- COUNCIL  DIRECTIVE  81/851/EEC  of  28  September  1981  on  the  approximation  of 
the  Laws  of  the  Member  States  relating  to  veterinary  medicinal  products 
(O.J.  n°  L 317  of  6.11.81). 
- COUNCIL  DIRECTIVE  81/852/EEC  of  28  September  1981  on  the  approximation  of 
the  laws  of  the  Member  States  relating  to  analytical,  pharmaco-
toxicological  and  clinical  standards  and  protocols  in  respect  of  the 
testing of  veterinary  medicinal  products  (O.J.  n°  L 317  of  6.11.81). 
- COMMISSION  COMMUNICATION  on  parallel  imports  of  proprietary  medicinal 
products  for  which  marketing  authorizations  have  already  been  granted 
(O.J.  n°  C 115  of  6.5.82). 
-COUNCIL  DIRECTIVE  83/570/EEC  of  26  October  1983  amending  Directives 
65/65/EEC,  75/318/EEC  and  75/319/EEC  on  the  approximation  of  provisions 
Laid  down  by  law,  regulation  or  administrative  action  relating  to 
proprietary medicinal  products  (O.J.  n°  L 332  of  28.11.83). 
COUNCIL  RECOMMENDATION  83/571/EEC  of  26  October  1983  concerning  tests 
relating  to  the  placing  on  the  market  of  proprietary  medicinal  products 
(O.J.  n°  L 332  of  28.11.83). 
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-COMMISSION  COMMUNICATION  on  the  compatibility  with  Article  30  of  the 
EEC  Treaty  of  measures  taken  by  Member  States  relating  to  price  controls 
and  reimbursement  of  medicinal  products  (O.J.  n°  C 310  of  4.12.86). 
- COUNCIL  DIRECTIVE  87/18/EEC  of  18  December  1986  on  the  harmonization  of 
laws,  regulations  or  administrative  provisions  relating  to  the  application 
of  the  principles  of  good  laboratory  practice  and  the  verification  of 
their  applications  for  tests  on  chemical  substances  (O.J.  n°  L 15  of 
17.1.87). 
-COUNCIL  DIRECTIVE  87/19/EEC  of  22  December  1986  amending  Directive 
75/318/EEC  on  the  approximation  of  the  laws  of  the  Member  States  relating 
to analytical,  pharmacotoxicological  and  clinical  standards  and  protocols 
in  respect  of  the  testing of  proprietary medicinal  products  (O.J.  n°  L 15 
of  17.1.87>. 
- COUNCIL  DIRECTIVE  87/20/EEC  of  22  December  1986  amending  Directive 
81/852/EEC  on  the  approximation  of  the  laws  of  the  Member  States  relating 
to analytical,  pharmacotoxicological  and  clinical  standards  and  protocols 
in  respect  of  the  testing  of  veterinary  medicinal  products  (O.J.  n°  L 15 
of  17.1.87). 
-COUNCIL  DIRECTIVE  87/21/EEC  of  22  December  1986  amending  Directive 
65/65/EEC  on  the  approximation  of  provisions  laid  down  by  law,  regulation 
or  administrative  action  relating  to  proprietary  medicinal  products 
(O.J.  n°  L 15  of  17.1.87). 
- COUNCIL  DIRECTIVE  87/22/EEC  of  22  December  1986  on  the  approximation  of 
national  measures  relating  to  the  placing on  the  market  of  high  technology 
medicinal  products,  particularly  those  derived  from  biotechnology 
(O.J.  n°  L 15  of  17.1.87). 
COUNCIL  RECOMMENDATION  87/176/EEC  of  9  February  1987  concerning  tests 
relating  to  the  placing  on  the  m<'lrket  of  proprietary  medicinal  products 
(O.J.  n°  L 73  of  16.3.87). 
N.B.  The  texts  adopted  before  1984  are  contained  in  a  publication  entitled 
--"The rules  governing  medicaments  in  the  European  Community",  on  sale  at 
the  Office  for  Official  Publicntions  of  the  European  Communities, 
L-2985  Luxembourg,  catalogue  number  CB-41-84-515. 
The  guide  entitled  "Notice  to  applicants  for  marketing  authorizations 
for  proprietary  medicinal  products  in  the  Member  States  of  the  European 
Community  on  the  use  of  the  multi-state  procedure  created  by  Council 
Directive  83/570/EEC"  is  also  on  sale  at  the  Office  for  Official 
Publications  of  the  European  Communities,  L-2985  Luxembourg,  catalogue 
number  CB-47-86-163. 
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ANNEX  II 
MAIN  DATA  ON  THE  PHARMACEUTICAL  SECTOR 
1)  INTERNATIONAL  TRADE  OF  PHARMACEUTICALS  IN  1986  (NIMEXE  30) 
11)  Imports  in  thousands  of  ECU 
12)  Imports  in  market  share  (%) 
13)  Exports  in  thousands  of  ECU 
14)  Export  in  market  share  (%) 
2)  EVOLUTION  OF  EXTRA  AND  INTRA-EEC  TRADE  OF  MEDICAMENTS,  INCLUDING  VETERINARY 
l"lEDlCINES,  (1981-1986)  (NIMEXE  30.03) 
21)  Imports  (Millions  of  ECU) 
22)  Exports  <r~il Lions  of  ECU) 
3)  PENETRATION  OF  EEC  MARKET  BY  COMPANIES  OF  VARIOUS  ORIGIN  IN  1984 
31)  Sale  in  millions  of  US  ~  (retail  pharmacies  at  manufacturers'prices) 
32)  % of  EEC  market  held 
33)  % of  Local  market  held 
34)  Home  sales  on  % of  EEC  sales 
4)  PHARMACEUTICAL  PRICES  AND  CONSUMPTION  IN  THE  EEC 
41)  Indices  of price  Levels 
42)  Consumption  per  capita  :  in  US  ~  (1984),  as  %of  GDP  (1984)  and  as  %of 
health  care  costs  (1983) 
5)  PHARt·lACEUTICAL  RESEARCH  AND  DEVELOPMENT 
The  top  100  companies  in  1987 
<EEC  companies  underlined). NIMl X[ 
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1.  INTERNATIONAL  TRADE  OF  PHARMACEUTICALS 
I  NHlEXE  30,  SOURCE:  EUROSTAT  I 
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2)  EVOLUTION  OF  EXTRA  AND  INTRA-CEC  TRADE  OF  MEDICAMENTS  (INCL.  VETERIN.MEDICAM.) 
(NIMEXE  30.03,  SOURCE  EUROSTAT) 
2  1.  IMPORTS  (~1io  ECLJ)  Code  NH1EXE  30.03  (EUROSTATl 
Year/To  EEC  DE  FR  I 
IT  NL  B/L  Ul<  IR L  Dl<  GR  ES  I PO 
1981  2247  598  162  226  298  31,0  33lt  107  1  01  ?8 
intr<l  EEC  15 85  361  124  160  21+5  25?  228  1  OS  58  lt3 
1982  2581  674  173  269  3lt9  368  431  11?  12!,  72 
intra  EEC  1813  408  132  179  27 t,  278  302  114  77  46 
1983  2985  778  196  325  387  lt24  520  134  137  80 
intra  EEC  2085  465  152  213  303  322  367  126  80  53 
198!,  .3625  882  2)2  lt28  588  t,s 6  619  151  159  86 
i nt r<l  EEC  2592  525  191  267  503  347  453  1lt2  99  62 
1985  4044  1033  310  52ft  (J 12  495  638  164  179  86 
intra  EEC  2900  631  235  327  516  383  !,74  156  11 0  64 
1986  4551  1085  363  602  630  544  695  161  209  93  72  97 
intru  EEC  3077  657  266  357  528  426  520  153  129  68  43  70 
---
2  2.  EXPORTS  (Mia  ECU)  NH1EXE  30.03  (EUROSTATl 
Year/Frorn  EEC  DE  .  FR  IT  NL  EJ/L  UK  IRL  DK I  GR 
I 
ES  I  PO 
11981  4567  1192  918  290  306  lt65  1 091  57  218  24 
intra  EEC  1576  356  283  76  160  268  317  38  72  1 
1982  5 223  13Lt5  1  021  31t5  361  522  1227  85  280  33 
I. 
l1ntra  EEC  1180  495  333  87  175  299  399  58  98  3 
I 
11983  5817  1  t,?o  1159  t,oo  lt01  603  1300  1  OS  338  35 
1intra  EEC  2108  472  380  105  203  331  420  72  116  5 
I 
I 
j1984  6816  1683  129/t  lt64  60ft  695  1492  135  339  1,6 
!intra  EEC  2484  566  451  148  227  366  503  89  125  7 
1985  7638  1876  11,99  559  576  735  1731  11,6  1,61,  47 
intra  EEC  2895  671  54  211  21,7  396  563  100  145  9 
1986  9801  1998  1548  509  568  71,6  1596  159  494  36  135  14 
intra  EEC  3186  758  580  212  278  !,31  567  11 0  174  14  59  3 ORIGIN  OF  COMPANY 
~ 
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3.  PENETRATION  OF  EEC  MARKET  BY  COMPANIES  OF  VARIOUS  ORIGIN 
IN  1984  (RETAIL  PHARMACIES)  - Economists  Advisory  Group 
BE  DK  DE  GR  ES  FR  IR  IT  NL  PO  UK  us 
41  5  42  46  7  12.  51  168 
8  120  32  14  3  5  27  5 
70  18  1938  176  32  69  171  683 
3  4  31  30  9  3  24  so 
14  9  161  361  48  31  6  85  176 
80  17  246  1775  11  56  156  726 
1  3  5  3  1  22  30 
9  11  369  125  1061  28  16  221  511 
8  10  46  25  3  40  76  116 
4  - 20  7  3  31  13  61 
20  33  165  60  6  14  513  614 
258  230  3055  30  361  2288  1  1157  233  47  1359  3140 
BE  DK  DE  GR  ES  FR  IR  IT  NL  PO  UK  us 
1.8  1.7 22.4  <  1  2.6 16.8  <  1  8.5  1.7  (1  10  23 
10  48  63  16  35  54  1  40  17  18  32 
16  45  63  100  100  78  100  92  17  66  38 
CH  sw  TOTAL 
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379  58  359~ 
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4.  PHARMACEUTICAL  PRICES  AND  CONSUMPTION 
BE  DK  DE  GR  ES  FR  IR  IT  NL  PO  UK 
!1  1 •  PRICE  INDEX  .................... 
EFPIA,  1985  100  170  109  103  160  142 
(BE  •  100) 
BEUC,  1987  80  153  61  69  142  72  140  123 
(EEC  •  100) 
EUfWSTAT,  1985  94  134  160  63  69  77  127  83  140  63  76 
EUR  12  = 100 
t  2.  CONSUMPTION 
____  a. ______ 




in  US  $  64  53  89  32  34  73  33  59  33  25  44 
( 1984) 
as  1,  of  GDP  0.81  0.50  0.89  0.95  0.81  0.81  0.67  0.91  0.38  1.08  0.59 
(1984) 
as  1,  of  health  8.6  7.0  11.0  20.2  12.1  8.8  8.8  12.4  4.1  18.9  9.6 
care  cost <1983) - 32  -
5)  PHARMACEUTICAL  r~ESEARCH  AND  DEVELOPf~ENT_ : 
The  top  100  comp~nies in  1987,  Ph~rmilprojccts,  1n  SCRIP  N°  1270  J~n 1st/ 
6th  1988,  (EEC  companies  unJcrl incd) 
Position 
1987('86) Companv 
1  (2)  Merck & Co 
2  (3)  Bristoi-My.,rs 
3  (4)  Ciba-Geigy 
4 .• D.L~ 
5  lUI  Lrlly 
G  151  SmithKiinl' 
7111)  J&J 
81131  Rhone ·Poulenc 
n l\J)  tioche ·--
1  0  (G)  Warner-Lambert 
Subtotal: top 10 
11(10)  El;m' 
i2  ... (~\v;:l  ;~;"nf' 
13I12I''Tiir;;-cr.;··· 
14( 14)  Up1ohn 
15118)  Sandoz 
1fii21)  Monsanto 
17(15)  AmHomeProd 
18(10)  8eecham 
i~E72.... sch-~~ 
20122)  Pitzer 
Subtotal: top 20 
21123)  Fupsawa 
(?IJ Ill  .. n'!!:h!  m ..  1,_,  I  no 
:nj201  F!ou~';"l Uclaf 
24(27j ~~(~FN.-~:0~!.... 
2C>(30)  1\rn Cyanamid 
7t~'31).  flwycr 
:0/1:14)  ICJ __ 
2i'(;'~l  A';tr.J 
;>~JI74)  Sanofr 
301281  Synt"x 
Subtotal: top30 
J 1  (  2f,)  Scherinq-Piough 
3:'(--)  F\t>st•.Jrch Corp' 
3:11311  Yarnanouchr 
>:!331  s~nkyo 
'l~>it;41  . Gld<O 
JG(:t21  ~;qurbb 
371381  Genentech 
381251  Merrell Dow 
301481  Abbott 
~0\~t>J._iir~PJL 
Subtotal: top 40 
41 (351  Sterling Druq 
42l·lf>l  Ocwhrrn<:l"' Mann 
.J)('A-;i  Merp·S,;rk.J .... - ·  . 
·1·li.J!.>I  Kyowa Hakko 
·l~·l:t!JJ  Sumrtm11c> 
.l(;(<i21  E"J' 
411-1  PharrnJcrJ 
481!.>5)_  --~tll':'"'t'. 
49IS1J  Slllono<jl 
SOif•71  MctsodH,,Ill Cl11,m 
SulJiotdl  111p SO 
Compounds in R&D 
No of  No of  No under 
R&D drugs  own drug.s  licence 
110  85  25 
103  77  2G 










7G  21 
73  15 
64  24 
64  21 
60  24 
5G  24 
65  14 
G90(14.4%)  222(16.5%) 
76  0 
75  61  14 
73  60  13 
65  48  17 
G5  46  19 
G2  40  22 
60  37  23 
50  56  3 
5!l  47  11 
58  37  21 
1,563(25.5%)1,198(25.0%) 3G5(27.1%) 
57  45  12 
57  43  14 
51  25  2G 
49  42  7 
47  34  13 
4G  40  6 
45  40  5 
45  2G  19 
44  40  4 
44  33  11 
2.048I33.4%)1,5GG(32.7%) 482(35.7%) 
43  35  8 
42  42  0 
42  23  19 
41  31  10 
40  30  10 
40  28  12 
38  34  4 
38  33  5 
38  26  12 
37  30  7 
2,447(39.9%)1,878(39.2%) 5G9(42.2%) 
33  29  4 
32  25  7 
32  21  11 
31  25  6 
31  20  11 
29  24  5 
20  24  5 
29  22  7 
29  14  15 
27  20  7 
2, 749(44.8"•o)2,102(43.9%)  G47(48.0%) 
Position  No of  No of  No under 
7987('86) Company  R&Ddrugs  owndrugs  licence 
51 (50)  Dniichi Sciynku  26  14  12 
52(42)  DuPont  26  14  12 
53(41)  GrconCross  25  18  7 
54{57)  Yoshitomi  25  17  8 
5!iL54l,...&JoPhan:n.!!  25  16  9 
?~tG_G.l_.,_£f.C2!~ati_  25  12  13 
57(40)  Alzn  24  24  0 
58(43)  Yissum  24  24  0 
59(52)  Chiron  24  21  3 
G0(49)  Teijin  24  21  3 
Subtotal: top 60  2,997(48.8%)2,283(47.7%) 714(52.9%) 
G1 (72)  Otsukn  24  19  5 
62(59)  Roror  24  19  5 
6~{1].b.Clr:ruL~!L  24  18  6 
64(74)  AHRobins  24  15  9 
G5(73)  Dainippon  23  15  8 
6G(80)  Tnisho  23  15  8 
G7(58)  Kaken Pharmn  23  14  9 
68(-)  BTG  22  22  0 
69(64}  Chinoin  22  21 
70(G3}  TanabeSeiyaku  22  18  4 
Subtotal: top 70  3,228(52.6%)2,459(51.4%) 7G9(57.0%) 
71(83)  NovnPharma  22  17  5 
72(:::;-J._jJo,QtS  21  17  4 
73(61l' ·cFiuiJili  21  11  4 
Hill.7.l  E  Mrr~!..  21  16  5 
75(69)  Pan Medica  20  20  0 
7G(-)  Phnrmatoc (US)  20  20  0 
77J9SL fl~iersdorf  20  19  1 
?.?1=-l-.~9.':'9.  20  18  2 
79(70)  H G Pars  19  19  0 
80(G5)  f!ykGulden  19  17  2 
-sub'icital:tc;poo  3.431(55.9%J2,G39(ss.1%J  792(58.7%1 
81(-)  S S Pharmacoutical  19  1  G  3 
82(75)  California Diotech  18  17 
83(60)  Richter  18  17  1 
84(89)  TheliposomcCo  18  16  2 
85(-)  Ono  18  16  2 
IJ.f!(7.G))~i.qr.wfab~e.  18  1G  2 
87(84)  Reckitt & Colman  18  16  2 
1iarsar)IC(J';)--···~---·- 1a  1G  2 
89(-)  Ajinomoto  18  15  3 
90(81)  Nippon Knyaku  18  11  7 
Subtotnl: top 90  3,612(58.9%)2,795(58.4%)  817(GO.G%) 
91 (78)  Oiogen  17  15  2 
_tl.419.H ...  ii~P'29,  17  7  10 
93(-)  Enstman Kodnk  17  1  16 
9-1{-)  Pennwalt  16  16  0 
95(87)  SRIInternational  16  15  1 
96(-)  Procterf" Gamble  16  13  3 
97(97)  CDC life  Sciences  16  11  5 
98(90)  KabiVitrum  16  11  5 
~9J:::::J •.  ~J.!l'!!.I!.T!JU  16  9  7 
1 00(-)  Hereon  15  15  o 
Subtotal: top 100  3,774(61.5%)2,908(G0.7%)  8GG(64.2%) - 33  -
ANNEX  III 
COMPOSITION  OF  THE 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS - 34  -
COMITE  DES  SPECIALITES  PHARMACEUTIQUES 
COMniTTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
President  I  Chair~an 
Dr.  C.A.  TEIJGELER 
Vice-Presidents  I 
Deputy  Chairmen 
Dr.  G.  JONES 
M.  F.  SAUER 
Voorzitter  College  ter beoordeling  van 
geneesmiddelen, 
Ministerie van  Welzijn,  Volksgezondheid 
en  Cultuur 
Postbus  5811 
NL-2280  HV  RIJSWIJK 
Tel.:  <31)(70)  40.79.11 
Telefax:  (31)(70)  20.17.03 
Senior  Principal  Medical  Officer, 
Department  of  Health  and  Social 
Security,  Medicines  Division 
r~arket  Towers 
1  Nine  Elms  Lane 
LONDON  SW8  5NO 
Chef  de  Service 
Commission  des  Communautes  europeennes 
Direction generale  du  Marche  interieur 
et  des  Affaires  industrielles 
Service  "Pharmacie,  medicaments 
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Date  of  marketing  authorization. 
Date  of  refusal  or  withdrawal  from  the  market. 
Country  of  "origin"  which  granted  the  initiul  uuthorization 
on  which  the  procedure  wus  bused. 
Dute  of  Lust  information  transmitted  by  the  Member  State  as  a 
follow-up  to  the  opinion  of  the  Committee. 
Country  not  concerned  in  the  procedure. 
GRADING  =  Grading  of  the  opinion  of  the  Committee  using  the  following 
criteria  : 
( 0)  no  objection,  no  opinion  by  the  CP~1P  (no  cas e) 
(1)  favouruble  opinion,  except  for  formal  reservations  (  2  cases) 
(2)  favourable  opinion,  except  for  technical  reservutions  ( 18  cases) 
(3)  favourable  opinion  by  a  Large  mujority  3  cases) 
(4)  favourable  opinion  by  a  small  majority  5  cases) 
( 5)  linfavourable  opinion  by  a  small  mujority  6  cases) 
(6)  unfavouruble  opinion  by  a  Lurge  majority  2  cases) 
(7)  unanimously  unfavourable  opinion  (not  count in·]  the  5  cases) 
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··------ -· 
p  A  y  s  I  c 0  UN  T  R  I  E  s 
ML D  I C  AMEI/f 
Op 1n lOr 
II  DK  0[  F  GR  IRL  IT  LUX  NL  UK  No 
---1-------·---1---------------- IRJ 
AUT  fdJT  .  .  .  AUT.  AUT  AUT  OR  CEFACLOR  1 
14. 9. 79  29.5.79  *  31.10.80  21.11.82  21.8.79  21.8.78  CEFACLOR  20.4 :7'1  --'--
CONOVA  30  \HJ  2  AUT  AUT  •  •  •  AUT"  AUT  AUr  AIJT  OR 
OESTR.  CCffilN  20.4.79  29.7.80  22.11.79  8.3.79  :50.9.81  16.6.80  17.6.80  14.10.77 
fl(NAC  (R)  J  RU  REF  R(f  REF  •  •  REf  AUT  REF  OR 
fENCLOf(NAC  ~ ·'•.  HO  12.5.80  6.7 .!JI,  23.5.80  16.5.80  22.10.81  17.1.83  28.5.80  16.5.78  7 
SYNTAR IS (R)  I,  AUT  •  •  AUT  •  AUT  AUT  AUT  AUT  OR 
fLUN I SOLI 0  ' .I, .80  (2.1/.8~  21.5 .80  11.7.80  7.7.82  22.9.82  19.4.82  29.3.78 
l YCAMED  (RJ  5  OR  AUT  AUT  •  *  Rff  INF  AUT  AliT  REf 
LYSINO- CALC.  0.2 .B-1  1. 8. 79  26.3.81  22.9.81  22.4.83  7 .10.'86  2.6.62  6.1.1\2  30.12.81 
DIOI'INE  (RJ  6  AUT  /diT  OR  *  •  •  AUT  *  AliT  AUT 
DIPINEFRIN  2 0  5 .81  16.4.82  I, .6.81  19.7.78  31.12.83  3.12.81  27.10.83 
.. 
1\CET ARD  (RJ  7  AUT  OR  AUT  •  •  AUT  *  AUT  AUT  AUT 
A.S.A.  0.2.81  1H.5.8~~  2.7.80  7.9.81  2.2.84  ?.9.9.82  26.1.82  10.5.83 
0  ·-f--------·------- -
OPREN(RJ  8  RCF  REF  •  .  *  •  REF  REF  REF  OR  I  REF 
ElENOXAPROfEN  D. 2 .R1  6.8.82  (.I, .l\1  6.8.82  6.8.82  {6.8.82  4.8.1982 
(R)  +--- !-------------- r-·· 
fl 0GAR  'I  OR  n  r· r  REF  REF  REF  REf 
OX Mil  T i\1: ltl  1(1.3.111  '"·,·'"'If.,·'" 
.  .  •  10.3.81  •  7.6.82  6.1 .82  10.5.1l2 
------- --------- -·  t--· 
rREST!I-1[  (R!  10  AUT  AUT  AUT  AUT  •  *  •  ·AUT  AUT  OR 
T  HIOLOL  CCffil~  110 ..  1.1\1  11.5.32  :  .• 10.UI,  3 011  .111  l/o. I,. 31  25.1 .82  24.5.82·  6.6.79 
1\AJ.I NUHM  CRJ  11  Alii  (;/!  AUT  •  *  AUT  •  AliT  AUT  AUT 
POTASSIUM  c  l  12 .) .81  6 .I.  82  7.  'j 0  79  6,8.81  24.1.83  25.1.83  3.11.111  7.12.83 
SUPROL (R)  12  .  REF  !AUT  _  !  AUT  REF  REF  LAUT  I! AUT  OR/REF 




DlDROt/EL iRl  I  13 
AUT  AUT  •  *  *  AUT  *  AUT  AUT  OR 
ET I DROll/< T  7.7.li1  1.7.82  7.2.83  30.7.82  17.1.83  13.9.82  14.11.80  3 
tHCORETTE  (Rl  14  AUT  2  rng  AUT  2  mg  AUT  AUT  2  mg  *  *  AUT  AUT  AUT  OR 
N1  COT IN  7.10.81  14.10.83  9.3.84  27.12.82  19,7  85  31.12.83  17.1.83  17.3.83  20.8. 79  6 
lDURlDlN (RJ  15  AUT  OR  AUT  REF  *  *  AUT  AUT  AUT  *  lOOXURIDIN  7.10.81  24.2.83  6.1.78  8.12.82  29.7.82  31.12.83  29.9.82  25.3.83 
(5  X> 
4 
PULMOCLASE(R  16  OR  REf  AUT  *  AUT  *  AUT  *  REF 
CARBOC!STEIN 9.12.81  20.5.80  3.12.85  •  7.8.86  8.2.83  29.9.82  28.9.82  5 
ECUIBAR  (R)  17  AUT  .  AUT  OR  *  *  AUT  AUT  AUT  AUT 
METHYLOOrA  7.4.82  3.83  3.5 .83  22.12.80  31.12.83  Z1  .• 2 .83  1.8.83  26.1.83  2 
SELEXID  (R)  18  AUT  or~  AUT  AUT  *  *  AUT  AUT  •  . 
M[CILL!NM1  r; JJ.  p,;~  :~. t1. H5  30 0  ~ 0  19  11.9.84  5.3.84  31.12.83  21.2.83  2 
----·---
CAR flO"  !LANE( 
J  1?  AUT  liEf  I  rcr 
AUT  OR  AUT  REF  AUT  AUT  RU 
bWUt/ ACT JVE  H.9.82  '· • .3. B3  17.6.87  27.8.84  16.2.81  4.4 .84  1S'.3.86  17.10.86  17.1.83  3.7.84  1. 1."86 
[lUSIUJJF_ 
6 
RYlii~IAIItllll  H  ;'II  Alii  .l  AUT  on  AUT  REF  AUT  AUT  AUT  . 
M1 f(l(I,'\Ji(J!(  'I.  •,'. ·''  .. '  i'. HI  2.  ~~HI,  23.11.111  6.12.84  3.3.87  31.12.83  17.1 .83  I, .3 .83 
-·-· . ------------------·- ---------- 41  -
-----------
I 
f'  A  y  s  I  c  0  lJ  tl  T  R  I  [  s 
-- - - ---------------
MEDICAMENT 
Opinion  [I  D~:  Dl  f  GR  IRL  IT  LUX  tJL  u~ 
I 
No 
VERRUMAL (R)  21  REF  REF  OR  REr  REF  •  lt/F  •  •  REF 
18.12.8  20.4.83  15,6,84  1. 11.78  15.7.86 
17.10.86  29.11.83  fLUOROURACI  10.10.84 
7 
PERSTORP  CRJ  22  REF  AUT  AUT  AUT  !NF  ltlf  AUT  AUT  AUT  OR 
CAOCX(t[.RE  I.  8.9.82  9.6.83  24.9.82  8,9,83  21.11. 85  30.7.81  25.4.83  18.10.83  14.8.81  14.2.85  30.6.86 
4 
FORAN[ (R)  23  OR  •  AUT  •  •  AUT  AUT  AUT  AUT  AUT 
JSOFLUORAN  18.11 .82  10.2.82  20,2 ,81.  31.8.82  31.12.83  17.1 .83  14.2 .83  23.3.83  2 
-
M!RAXID  (Kl  21,  nEF  AUT  AUT  REf  REF  •  REf  AUT  REF  OR 
PIVN'PJC!WN  18.11 .82  2.5.83  06.03.87  19,7.84  5.3.84  27.9.84  117.10.86  17.1 .83  21, .8 .83  30.6,81  5 
~) 
25  OR  AUT  •  REF  AUT  AUT  REf  THIBLOC  AUT  AUT  REF 
ZEIN  SCOIUI  28.1.83  14.12.87  15 .6.tll.  26.7.79  27.12.83  11.82  17.10.86  17.1 .83  13.5.85  21.8. 85 
~_IUf 
NALGOFAN (R)  26  AUT  •  RrF  OR  •  •  REF  AUT  AUT  • 
GLAHN IN  28.1 .83  25.5.83  20.7,84  26.3.82  17.10.86  21.2.83  2.6.83 
2 
KERLONE  (Rl  27  AUT  AUT  AUT  OR  .  AUT  UT  At)T  AUT  AUT 
UET AXOLOL  28.1 .83  11.5. 83  31.12 .82  7.9.83  10.5.82  4.3.86 
f5.6.:4 
21 .2 .83  8,8.83  15.7.83 
----
IBUMOIN(R)  28  AUT  en  AUT  •  •  AUT  AUT  AUT  AUT 
I8Uf'ROFEN  8.3.83  9.81,  22 .1 0.81  14.10,83  21. 1.C6  6.8.84  21, .2 ,81,  8.12.83 
2 
SAfliDAL  (R)  29  AUT  AUT  •  ltlf  AUT  AUT  AUT  AUT  AUT  OR 
TllcOPii IL.  11.5.83  6.3 ,81,  25.5.83  20.1.87  11J.BI,  2.2.86  30.7.<17  1 .8 .83  22 .8.81,  9.6.82 
4 
[lUOL!P  (Rl  30  R[f  fiEF  OR  •  •  tlc r  •  AUT  REF  REf 
CLOfiGR,  ET.  i 1 . 5. 83  28.10.83  3.12.  !l'J  28.3.80  8.2.83  20 .6.!l3  8.6.83  18.10.83  7 
--
(Rl  .II  .Ill if  on  AUT  AUi  ;. '  •. :T  f•UT 
Ill ',HAC·LAL  p,.  '• .w.  .  .  . 
'1 .'I .8 I  2). 2 . B  1  21, ,.9 .. B  I,  1.s.n  9.7.8)  25.10.8J 
M·"l:j>\l  [1rl/d 
----------- -----~  ~--------- ------
(Rl  -,'  Al!l  0i<  AUT  AUT  AUT  AUT  AUT  !IIGCTARl>  .  •  . 




33  R[f  AUT  AUT  on  REf  AUT  lNF  AUT  AUT  AUT 
At/A US IN 
~ .11.8:1  3.  9 ,IJI,  31 .H .Ht,  27.8 ,!JI,  27. 1?. 8  20.9.81,  11, .a .84  17.10.86  21.11.83  19.7.85  14 .3 .85 
ft:TOQcru/>MID 
·----
EXIREL <Rl  31,  AUT  AUT  AUT  AUT  JNF  OR 
11.1 .81,  •  •  •  •  30.7.87  10.4.36  21  . 5. 82  PIRBUTEROL  10.81,  1 .2 .PJ,  13.2 ,81, 
"'---- I  r.GrHAI  <nl  !;)  T<!  F  REf  011  .  I Nf  •  .  R"F  RU  • 
.  vERALJPR!U  11. 1./ll,  6.2 .HI,  6.:i . .SJ  3.12.79  28.3.81.  1.10.85  6.2 .f.  I, 
·------------- I 
( Rl 
IIIF  !NF  O!HCIL  36  REF  Rt:r  ~EF  •  REF  REF  ,1C:F  OR 
1  soo:uM  6.9.84  19.2,86  8.10.84  2.  9 .B 5  2'·· 10.8  11.2. 86  27.11 .81,  18.3.85  15. 10. {>4  31 .1.83 
i  --~-ALl  CY LA T 
i GPTIMIIIE(RJ  37  *  AUT  * 
.It  if  .  .  Oil 
II·IATArdtiL  /1AI  P.£F  /IUT  AUT 
31. L'.B'J  30.5.85  1t,.?.Wi  2<'.1.R5  17.10.86  J. 12. A  1  14. 11.81 
? 
- -- 1--------------
'\C,l  corn !llll\K  .'Ill  IIIII  .  •  /Ill 1  AliT  011  HI f  AliT  AUI  . 
'\l•id'HI nr 
1 ')./,. H'• 
;?U,t, .or~  2.).  f,()  16. 1  D. 8'  17.10.86 1 •. 10.85  1 J. 2 .l~6 
____ _j  l.'l.fl!.~LL_ ------------1------ --
:·!.~Ct~S[  (R)  f,iJJ  AUT  JIH  AUT 
IIIHlllP(,I
1 /,JU  Y/  Ol;  3 . 1  .~ • 8  ~)  *  •  11.11.  8t  •  17.10.86  z~. z.  et~  _'_j  __  · -- u.  11 .II'  16.3.84 
------·-- -~------ -- ----:-----
',•n1u1r'q ll (R)  I  :-fi 
/,[1  AUT  Hlr  .  AUT  ALIT  •  R  t 
HYDROOilOROTtHA- 11,2. Alo  3.6.87  21  ·'· .86  *  1.8.86  21. 4. 86 
llDC--------- ---------- I  - ~--
t'Jf,'II..  <  Rl  INF  1,1  AUT  AUT  AUT  ()1\  •  *  .  AUT 
22.9.8  *  '/1/(l'llllllfTCl~  15.10.87  6.6.86  21.4.86  1 ;
1
•  ,>. h(l  25.5.79 
-- -.  ---. ~- --- ------------1 - 42  - ANNEX  V 
CPMP  MULTI-STATE  APPLICATION  SEQUENCE 
DIRECTIVE  83/570/EEC 
1.  A firm  applying  to  use  the  multi-State  procedure 
- consults  the  competent  authority  which  granted  the  initial authorisation, 
agreeing  any  additions  to  be  made, 
- submits  a  complete  dossier  to  the  other  Member  States  concernej  with 
the  application,  asking  them  to  take  into  due  consideration  the 
initial authorisation  (minimum  of  2  other  Member  States), 
- notifies  CPMP  secretariat  (Committee  of  Proprietary  Medicinal  Products). 
2.  CPMP  secretariat  sends  a  telex  to all  Member  States,  stating  the  name  of 
the  company  and  the  product,  the  original  country  of  authorisation and 
Lists  countries  concerned.  Concerned  States  are  thereby  invited  to notify 
receipt  of  the  dossier  to  the  CPMP  secretariat.  ALL  available  assessment 
reports  relating  to  the  same  product  are  immediately  communicated  by  the 
:ompetent  authorities  to  the  Member  States  concerned  and  to  the  Committee. 
3.  Concerned  Member  States  confirm  receipt  of  complete  application  <by  telex 
or telefax,  usually)  to  the  secretariat.  When  all  concerned  countries  have 
responded,  the  120  day  period of  consideration  commences.  Only  one  telex 
per  month  will  be  sent,  notifying  the  commencement  of  the  120  day  period 
for all  multi-State  applications  in  that  month. 
An  opinion  of  the  CPMP  is  not  required,  if no  Member  State  puts 
forward  any  reasoned objection  during  the  120  day  period. 
4.  In  exceptional  cases,  if there  are  reasoned  objections within  the  120  days, 
the  Member  State  concerned  notifies directly  to  the  applicant  and  the 
original  authorising  country.  A copy  is also  sent  to  the  CPMP  secretariat 
for  information. 
5.  After  receiving  all  reasoned objections,  the  rapporteur  enters  into 
consultation with  the  applicant.  The  time  needed  by  the  applicant  to  respond 
is  agreed.  If  an  extension  of  the  time  is  necessary,  the  rapporteur  informs 
the  secretariat  of  the  Committee.  The  secretariat  thereafter  informs  the 
Member  States.  A tentative date  for  the  adoption  of  the  opinion  of  the 
Committee  is established. - 43  -
6.  In  response  to  the  reasoned  objections,  the  applicant  prepares  a  single 
rc~ction to  each  of  the  objections  raised  (questions  +  answers).  The 
format  of  this  response  to  be  the  same  sequence  as  the  dossier  Ci .e. 
Notice  to  Applicants  format). 
7.  The  company's  response  to  be  circulated  to all  members  of  the  CPMP,  by 
name,  Least  30  working  days  before  the  date  of  the  meeting  as  agreed 
with  (point  5)  the  company  in  the  format  of  Notice  to  Applicants. 
3.  If  the  company  wishes  an  oral  presentation  (hearing),  this  would  be 
confirmed one  month  in  advance. 
9.  The  rapporteur  keeps  the  CPMP  informed  of  the  progress  of  the  application. 
10.  At  the  CPMP  meetin~,  the  rapporteur  reports  on  the  resolution  of objections. 
The  hearing  Cif  any)  takes  place.  The  secretariat  drafts  the  opinion 
after  the  discussion  and/or  hearing  which  the  Committee  adopts  the  second 
day. 
11.  Within  60  days  of  the  issue of  the  Opinion,  the  Member  States  concerned 
notify  the  Commission  of  their  decision  taken  regarding  the  application. - 44  -
ANNEX  VI 
STANDARD  FORMAT  FOR  APPLICATIONS  IN  THE  EEC 
(NATIONAL  AND  COMMUNITY  PROCEDURES) 
PART  I: 
SUMMARY  OF  THE  DOSSIER 
PART  II: 
CHEMICAL, 
PHARMACEUTICAL  AND 
BIOLOGICAL 
DOCUMENTATION 
PART  III: 
TOXICOLOGICAL  AND 
PHARMACOLOGICAL 
DOCUMENTATION 
PART  IV: 
CLINICAL 
DOCUMENTATION 
PART  V: 
SPECIAL  PARTICULARS 
I  A - Administrative data 
I  B - Summary  of  product  characteristics 






pharmaceutical,  toxicological/ 
pharmacological  and  clinical 
documentation 
Composition 
Method  of  preparation 
c - Control  of  starting materials 
II  D - Control  tests on  intermediate products 
II  E - Control  tests on  the  finished  product 
II  F - Stability 
II  Q  - Other  information 
III  A - Single dose  toxicity 
III  B - Repeated  dose  toxicity 
III c - Reproduction  studies 
III  D - Mutagenic  potential 
III  E  - Oncogenic/carcinogenic  potential 
III  F  - Pharmacodynamics 
III  G - Pharmacokinetics 
III  H - Local  tolerance 
III  Q - Other  information 
IV  A - Human  pharmacology 
IV  B- Clinical documentation 
IV  Q  - Other  information 
V A - Dosage  form 
V 8  - Samples 
V C - Manufacturers  authorization(s) 
V D - Marketing  authorization(s) 
. I •. - 45  - ANNEX  VII 
"HIGH-TECH"  CPI11P  CONCERTATION  APPLICATION  SEQUENCE 
DIRECTIVE  87/22/EEC 
1.  A firm  applying  to  use  the  concertation  procedure 
- for  Biotech  :  requests  the  first  Member  State  to act  as  rapporteur; 
- for  other  Hi~htech  :  also  requests  the  first  Member  State to accept 
the  application  as  suitable  for  the  procedure  (the  Member  State  may 
refer  the  matter  to  the  CPMP  for  agreement). 
2.  The  company  makes  a  formal  application  to  the  first  Member  State  who  acts 
as  rapporteur  thereafter,  and  notifies  the  CPMP  of  the  application. 
3.  The  company  makes  a  complete  application to  as  many  other  Member  States  as 
possible  and  supplies  (at  Least)  a  summary  of  the  dossier  to all other 
States,  certifyin~ that  dossiers/summaries  are  identical.  A full  dossier 
plus  a  summary  is  supplied to  the  CPMP. 
4.  The  commencement  of  the  procedure  is  determined  by  the  rapporteur  State 
and  communicated  by  the  secretariat.  Member  States  encountering  difficulty 
reGarding  receipt  of  an  application/summary  notify  the  rapporteur  State 
directly.  The  rapporteur  establishes  a  time-table  for  review  as  in  the 
Directives  (for  Bio/High  Technology  Applications  which  may  be  considered 
as  exceptional,  the  period of  review  would  usually  be  120  plus  90  days). 
5.  The  rapporteur  State  prepares  a  pre~iminary assessment  report.  ALL  Member 
States  are  invited to add  comment/questions  to this. 
6.  The  rapporteur  State  Liaises  with  the  company,  particularly  regardin~ 
questions  raised. 
- straight  forward  yuestions  may  be  answered  directly; 
- complex  issues  may  be  discussed  between  the  company  and  the  rapporteur, 
working  party or  CPMP. - 46  -
7.  In  the  event  that  substantial  additional  information  is  required,  the 
rapporteur  State  may  'stop  the  clock'.  Recommencement  of  time-Limits 
will  be  determined  by  the  rapporteur  State,  who  Liaises  closely  with 
the  company. 
8.  The  rapporteur  State  keeps  the  CPMP  informed  of  the  progress  of  the 
application,  and  confirms  the  date  for  finalisation of  the  CPMP  opinion. 
30  days  before  the  expiry  of  these  time-Limits,  the  CPMP  gives  its 
·' 




confirmed  one  previous  month  in  advance.  t 
The  company's  additional  documentation  to  be  circulated to all  membofs  of 
the  CPMP,  by  name  at  least  30  working  days  before  the  meeting,  in  the 
format  of  Notice  to  Applicants. 
10.  At  the  CPMP  meeting,  the  rapporteur  State  reports on  the  resolution of 
objections.  The  hearing  Cif  any)  takes  place.  The  secretariat  drafts  the 
opinion after  the  discussion  and/or  hearing  which  the  Committee  adopts 
the  second  day. 
11.  Within  30  days  of  the  issue of  the  opinion,  the  rapporteur  State and 
other  Member  States  concerned  notify  the  Commission  of  their decision 
on  the  action  to  be  taken  following  the  opinion  of  the  Committee. 
12.  The  Member  States  not  directly  concerned  inform  the  Committee  of  subsequent 
applications  for  marketing  authorisation. 
13.  Member  States  inform  the  Committee  in  advance  of  any  new  regulatory 
action  on  pharmacovigilance matters,  or  in  urgent  cases,  immediately 
thereafter. - 47  - ANNEX  VIII 
CONSEUUHJCES  OF  THE  ENTRY  INTO  FORCE  OF  DIRECTIVE  87/21 /EEC 
The  objective of  Directive 87/21 /EEC  is  to achieve  a  greater  degree  of 
harmonisation  in  the  rules of  the  Member  States  concerning  the acceptability 
of  abridged  applications  (which  do  not  contain  full  pharmaco-toxicological 
and  clinical  data)  for  authorisation  for  products  which  are  copies  of 
established proprietary medicinal  products.  Although  the  fundamental  aim  of 
the  Directive  is  to  improve  the  protection of  innovation,  the  Directive  in 
no  way  modifies  the  Legislative  rules  governing  the  authorisation  of 
innovatory  products,  for  which  full  data  must  always  be  provided.  The  directive 
is  solely  concerned  with  the  conditions  for  the  authorisation of  copies. 
It  follows  that  the  provisions  of  Directive 87/21 /EEC  apply  to all 
applications  submitted after  1  July  1987  for  authorisation  to market  Gopies 
of  established products  to the  competent  authorities  in  Belgium,  Denmark, 
Germany,  France,  Ireland,  Italy,  Luxembourg,  the  Netherlands  and  the  United 
Kingdom.  After  1  July  1987,  any  person  submitting  an  application  without 
full  supporting  data  in  those  countries must  show  that  the  conditions  set 
out  in  one  of  the  subparagraphs  (i),  (ii)  and  (iii)  in  Article  4  point  8  (a) 
of  Directive 65/65/EEC  as  amended  are  satisfied.  Where  the  applicant  seeks 
to  rely  on  sub-paragraph  Ciii),  he  must  show  not  only  that  his  product  is 
essentially  similar  to another  product,  but  he  must  also  demonstrate  that 
the  other  product  concerned  has  been  authorised  within  the  Community  for  at 
Least  six or  ten  years,  as  appropriate,  and  that  it  is being  marketed  in 
the  Member  State  concerned.  Since,  in  accordance  with  Article  12  of  Directive 
65/65/EEC,  all  decisions  to grant  marketing  authorisation must  be  published, 
this  should  not  present  any  undue  difficulty. 
So  far  as  the actual  Length  of  the  period of  time  for  which  the  second 
applicant  must  wait  before being  able  to  rely  upon  sub-paragraph  (iii)  is 
concerned,  the  current  situation  is  as  follows  : 
a)  Germany,  France,  Italy,  Belgium,  the  Netherlands  and  the  United  Kingdom 
have  informed  the  Commission  that  they  intend  to apply  a  period of  ten 
years  in  respect  to all  medicinal  products. - 48  - ANNEX  VIII 
It  should  however  be  noted  that  this  ten  year  period  runs  from  the  date 
of  the  first  authorisation  of  the  medicinal  product  in  the  Community, 
rather  than  the  date  of  the  authorisation  in  the  Member  State  concerned. 
b)  In  Denmark,  Ireland and  Luxembourg,  the  period  of  ten  years  protection 
will  initially  be  reserved  for  medicinal  products  developed  by  means 
of  one  of  the  three biotechnological  processes  mentioned  in  List  A of 
the  Annex  to  Directive 87/22/EEC  :  recombinant  DNA  technology;  controlled 
expression  of  9enes  coding  for  biologically  active proteins  in 
prokaryotes  and  eukaryotes,including  transformed  mammalian  cells; 
hybridoma  and  monoclonal  antibody  methods.  In  accordance  with  the 
principles outlined above,  this  ten  year  period  will  apply  notwithstanding 
that  the  product  concerned  was  first  authorised  in  the  Community  prior 
to  1  July  1987.  In  addition,  however,  the  ten  year  period of  protection 
will,  in  the  future,  also  apply  to  those  other  high  technology  medicinal 
products mentioned  in  List  B of  the  Annex  to  Directive 87/22/EEC  in 
respect  of  which  the  CPMP  has  given  an  opinion  pursuant  to  the  procedure 
provided  for  in  that  Directive.  So  far  as  other  categories of  medicinal 
products  are  concerned,  a  period  of  six  years  will  apply,  except  in  the 
case  of  Denmark  where  this  period  will  not  be  applied  beyond  the  date 
of  expiry of  a  patent  protecting  the original  product.  Once  again  it 
should  be  noted  that  these  six or  ten  year  periods  apply  from  the  date 
of  the  first  authorisation  of  the  product  in  the  Community  rather  than 
from  the  date  of  authorisation  by  the  Member  State  concerned  by  the 
application. 
c)  In  Greece,  Spain  and  Portugal,  special  provisions  apply  and  the  rules 
described  above  will  become  applicable  on  1  January  1992  at  the  Latest. 